Search Results - "Traets, Joleen J H"

Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling by Apriamashvili, Georgi, Vredevoogd, David W., Krijgsman, Oscar, Bleijerveld, Onno B., Ligtenberg, Maarten A., de Bruijn, Beaunelle, Boshuizen, Julia, Traets, Joleen J. H., D’Empaire Altimari, Daniela, van Vliet, Alex, Lin, Chun-Pu, Visser, Nils L., Londino, James D., Sanchez-Hodge, Rebekah, Oswalt, Leah E., Altinok, Selin, Schisler, Jonathan C., Altelaar, Maarten, Peeper, Daniel S.

“…The cytokine IFNγ differentially impacts on tumors upon immune checkpoint blockade (ICB). Despite our understanding of downstream signaling events, less is…”
Get full text

High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer by van den Broek, Evert, Dijkstra, Maurits J J, Krijgsman, Oscar, Sie, Daoud, Haan, Josien C, Traets, Joleen J H, van de Wiel, Mark A, Nagtegaal, Iris D, Punt, Cornelis J A, Carvalho, Beatriz, Ylstra, Bauke, Abeln, Sanne, Meijer, Gerrit A, Fijneman, Remond J A

“…Cancer is caused by somatic DNA alterations such as gene point mutations, DNA copy number aberrations (CNA) and structural variants (SVs). Genome-wide analyses…”
Get full text

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial by Nederlof, Iris, Isaeva, Olga I., de Graaf, Manon, Gielen, Robbert C. A. M., Bakker, Noor A. M., Rolfes, Adrianne L., Garner, Hannah, Boeckx, Bram, Traets, Joleen J. H., Mandjes, Ingrid A. M., de Maaker, Michiel, van Brussel, Thomas, Chelushkin, Maksim, Champanhet, Elisa, Lopez-Yurda, Marta, van de Vijver, Koen, van den Berg, José G., Hofland, Ingrid, Klioueva, Natasja, Mann, Ritse M., Loo, Claudette E., van Duijnhoven, Frederieke H., Skinner, Victoria, Luykx, Sylvia, Kerver, Emile, Kalashnikova, Ekaterina, van Dongen, Marloes G. J., Sonke, Gabe S., Linn, Sabine C., Blank, Christian U., de Visser, Karin E., Salgado, Roberto, Wessels, Lodewyk F. A., Drukker, Caroline A., Schumacher, Ton N., Horlings, Hugo M., Lambrechts, Diether, Kok, Marleen

“…Immune checkpoint inhibition (ICI) with chemotherapy is now the standard of care for stage II–III triple-negative breast cancer; however, it is largely unknown…”
Get full text

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma by Vos, Joris L., Elbers, Joris B. W., Krijgsman, Oscar, Traets, Joleen J. H., Qiao, Xiaohang, van der Leun, Anne M., Lubeck, Yoni, Seignette, Iris M., Smit, Laura A., Willems, Stefan M., van den Brekel, Michiel W. M., Dirven, Richard, Baris Karakullukcu, M., Karssemakers, Luc, Klop, W. Martin C., Lohuis, Peter J. F. M., Schreuder, Willem H., Smeele, Ludi E., van der Velden, Lilly-Ann, Bing Tan, I., Onderwater, Suzanne, Jasperse, Bas, Vogel, Wouter V., Al-Mamgani, Abrahim, Keijser, Astrid, van der Noort, Vincent, Broeks, Annegien, Hooijberg, Erik, Peeper, Daniel S., Schumacher, Ton N., Blank, Christian U., de Boer, Jan Paul, Haanen, John B. A. G., Zuur, Charlotte L.

“…Surgery for locoregionally advanced head and neck squamous cell carcinoma (HNSCC) results in 30‒50% five-year overall survival. In IMCISION (NCT03003637), a…”
Get full text

TSC2 regulates tumor susceptibility to TRAIL‐mediated T‐cell killing by orchestrating mTOR signaling by Lin, Chun‐Pu, Traets, Joleen J H, Vredevoogd, David W, Visser, Nils L, Peeper, Daniel S

“…Resistance to cancer immunotherapy continues to impair common clinical benefit. Here, we use whole‐genome CRISPR‐Cas9 knockout data to uncover an important…”
Get full text

The Elongin BC Complex Negatively Regulates AXL and Marks a Differentiated Phenotype in Melanoma by Schieven, Sebastiaan M, Traets, Joleen J H, Vliet, Alex V, Baalen, Martijn V, Song, Ji-Ying, Guimaraes, Marcos Da Silva, Kuilman, Thomas, Peeper, Daniel S

“…High expression of the receptor tyrosine kinase AXL is implicated in epithelial-to-mesenchymal transition, cancer progression, and therapy resistance. For…”
Get full text

Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness by Lin, Chun-Pu, Levy, Pierre L, Alflen, Astrid, Apriamashvili, Georgi, Ligtenberg, Maarten A, Vredevoogd, David W, Bleijerveld, Onno B, Alkan, Ferhat, Malka, Yuval, Hoekman, Liesbeth, Markovits, Ettai, George, Austin, Traets, Joleen J H, Krijgsman, Oscar, van Vliet, Alex, Poźniak, Joanna, Pulido-Vicuña, Carlos Ariel, de Bruijn, Beaunelle, van Hal-van Veen, Susan E, Boshuizen, Julia, van der Helm, Pim W, Díaz-Gómez, Judit, Warda, Hamdy, Behrens, Leonie M, Mardesic, Paula, Dehni, Bilal, Visser, Nils L, Marine, Jean-Christophe, Markel, Gal, Faller, William J, Altelaar, Maarten, Agami, Reuven, Besser, Michal J, Peeper, Daniel S

“…Genes limiting T cell antitumor activity may serve as therapeutic targets. It has not been systematically studied whether there are regulators that uniquely or…”
Get more information

An adverse tumor-protective effect of IDO1 inhibition by Kenski, Juliana C.N., Huang, Xinyao, Vredevoogd, David W., de Bruijn, Beaunelle, Traets, Joleen J.H., Ibáñez-Molero, Sofía, Schieven, Sebastiaan M., van Vliet, Alex, Krijgsman, Oscar, Kuilman, Thomas, Pozniak, Joanna, Loayza-Puch, Fabricio, Terry, Alexandra M., Müller, Judith, Logtenberg, Meike E.W., de Bruijn, Marjolein, Levy, Pierre, Körner, Pierre-René, Goding, Colin R., Schumacher, Ton N., Marine, Jean-Christophe, Agami, Reuven, Peeper, Daniel S.

“…By restoring tryptophan, indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors aim to reactivate anti-tumor T cells. However, a phase III trial assessing their…”
Get full text

Mechanism of life-long maintenance of neuron identity despite molecular fluctuations by Traets, Joleen Jh, van der Burght, Servaas N, Rademakers, Suzanne, Jansen, Gert, van Zon, Jeroen S

“…Cell fate is maintained over long timescales, yet molecular fluctuations can lead to spontaneous loss of this differentiated state. Our simulations identified…”
Get full text

High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer: e0138141 by Broek, Evert vanden, Dijkstra, Maurits JJ, Krijgsman, Oscar, Sie, Daoud, Haan, Josien C, Traets, Joleen JH, Wiel, A vande, Nagtegaal, Iris D, Punt, Cornelis JA, Carvalho, Beatriz

“…Background Cancer is caused by somatic DNA alterations such as gene point mutations, DNA copy number aberrations (CNA) and structural variants (SVs)…”
Get full text